Recent Pfizer Press Releases

  • 10/16/17 7:00 am EDT

    Strong, durable responses seen against lung tumors and brain metastases across multiple lines of therapy

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced full results from the Phase 2 clinical trial of the investigational, next-generation tyrosine kinase inhibitor lorlatinib that exhibited clinically meaningful activity against lung tumors and brain metastases in a range of patients with ALK-positive and ROS1-positive advanced non-small cell lung cancer (NSCLC), including those who were heavily pretreated. Further, side effects were generally manageable andmore...
  • 10/12/17 8:00 am EDT

    New formulation may offer convenience to patients

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the United States Food and Drug Administration (FDA) has approved LYRICA® CR (pregabalin) extended-release tablets CV as once-daily therapy for the management of neuropathic pain associated with diabetic peripheral neuropathy (pDPN) and the management of postherpetic neuralgia (PHN). LYRICA CR did not receive approval for the management of fibromyalgia. “LYRICA CR was developed to offermore...
  • 10/10/17 6:45 am EDT

    One of the Largest Over-the-Counter (OTC) Health Care Products Businesses

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced that it is reviewing strategic alternatives for its Consumer Healthcare business. A range of options will be considered, including a full or partial separation of the Consumer Healthcare business from Pfizer through a spin-off, sale or other transaction, and Pfizer may ultimately determine to retain the business. Today’s announcement is part of Pfizer’s continuing efforts to allocate resources and capital to bestmore...
  • 10/5/17 8:00 am EDT

    Pfizer Oncology Together provides dedicated social workers for people taking Pfizer Oncology medicines

    This is Living with Cancer™ provides innovative resources for all cancer patients

    NEW YORK--(BUSINESS WIRE)--Pfizer today unveils enhanced offerings to help patients manage their life with cancer. Pfizer Oncology Together is a first-of-its-kind program for patients taking Pfizer Oncology medicines that offers dedicated social workers called ‘Care Champions’ to help navigate the complexities that accompany treatment, such as identifying resources to help find emotional support, and workplace transition, transportation and financial assistance. Formore...
  • 9/27/17 8:30 am EDT
    NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc. today declared a 32-cent fourth-quarter 2017 dividend on the company’s common stock, payable December 1, 2017, to shareholders of record at the close of business on November 10, 2017. The fourth-quarter 2017 cash dividend will be the 316th consecutive quarterly dividend paid by Pfizer. Working together for a healthier world® At Pfizer, we apply science and our global resources to bringmore...
  • 9/26/17 9:21 am EDT

    LaBelle Seeks to Inspire Boomers 65 and Older to Get “A New Attitude” About Adult Vaccinations as Part of Pfizer’s All About Your Boom™ Campaign

    NEW YORK--(BUSINESS WIRE)--Like many Baby Boomers, award-winning entertainer and music icon Patti LaBelle takes steps to stay healthy, including exercising and eating right. Yet, despite being a health-conscious Boomer, LaBelle knows there are diseases that can take her out of her routine: such as pneumococcal pneumonia, a potentially serious bacterial lung disease.1 That’s why LaBelle has joined Pfizer Inc to help launch All About Your Boom™, a public awareness campaignmore...
  • 9/21/17 10:00 am EDT

    Pfizer, NNPA, and Howard University Collaborate to Improve Public Education and Awareness

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE), the National Newspaper Publishers Association (NNPA), and scholars from Howard University today announced results from a new national poll designed to deepen understanding and gauge perceptions around sickle cell disease (SCD) among African Americans. The poll, which included responses from adults in the US who self-identified as African American, revealed that while the majority of respondents were familiar with SCD andmore...
  • 9/20/17 9:10 am EDT

    Lawsuit Claims Johnson & Johnson Engaged in Unlawful Conduct to Stifle Competition From Inflectra

    NEW YORK--(BUSINESS WIRE)--To ensure patients and providers have access to important, lower cost biosimilar medicines, Pfizer (NYSE:PFE) today filed suit in the U.S. District Court for the Eastern District of Pennsylvania against Johnson & Johnson (J&J). The suit alleges that J&J’s exclusionary contracts and other anticompetitive practices have denied U.S. patients access to therapeutic options and undermined the benefits of robust pricemore...
  • 9/19/17 1:15 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration’s (FDA) Oncologic Drug Advisory Committee (ODAC) voted 6 in favor and 6 against the benefit-risk profile for SUTENT® (sunitinib) as adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma (RCC) after nephrectomy (surgical removal of the cancer-containing kidney). The role of the Advisory Committee is to provide recommendations to the FDAmore...
  • 9/19/17 10:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, October 31, 2017. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2017 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizermore...